March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
4 citations
,
September 2024 in “Jurnal Pengolahan Hasil Perikanan Indonesia” In this study, researchers reported that compounds from Bruguiera gymnorhiza leaves showed anti-inflammatory potential in in silico analyses, with favorable drug properties and specific binding to the IKKβ receptor, suggesting possible development into anti-inflammatory drugs.
January 2012 in “Methods in pharmacology and toxicology” This review discusses the expanding understanding of TRPV3's role in pain and skin pathology, while highlighting the need for further pharmacological research to fully resolve its functions.
This study found that 62 plasma proteins are significantly associated with the risk of obstructive sleep apnea, offering potential targets for new therapeutic strategies.
May 2025 in “Clinical Proteomics” In this study, researchers identified three proteins, DEFB1, HGFAC, and CYB5D2, as potential drug targets for alopecia areata, and suggested that the traditional Chinese medicine ingredient cimigenol shows promise in interacting with DEFB1 for potential treatment.
110 citations
,
February 2024 in “Journal of Chemical Information and Modeling” This study describes the PandaOmics platform, which uses AI and bioinformatics to identify new therapeutic targets and biomarkers for various diseases, demonstrating validation in laboratory and animal studies.
November 2025 in “Free Radical Biology and Medicine” This study identified ten potential therapeutic targets and biomarkers for androgenic alopecia, with SOD1 and KL as particularly promising candidates for future therapies.
This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.
17 citations
,
April 2023 in “Aging” In this study, the authors used AI-driven methods to identify and prioritize promising therapeutic targets that may address both aging and Glioblastoma Multiforme, proposing CNGA3, GLUD1, and SIRT1 as novel candidates.
15 citations
,
November 2022 in “Cell Death and Disease” In this study, the researchers identified CEP135 as a biomarker linked to poor sarcoma survival and suggested PLK1 as a potential therapeutic target for sarcoma patients with high CEP135 expression.
This study suggests that 9-Octadecenoic acid (Z)-, 2,3-dihydroxypropyl ester from African Yam bean seeds may inhibit the human 5α-reductase II enzyme, potentially helping manage BPH, although further studies are needed.
August 2025 in “Frontiers in Pharmacology” This study identified three Ayurvedic compounds that may serve as potential treatments against the macrolide-resistant enzyme murE of *Tropheryma whipplei*, addressing challenges in treating Whipple disease.
8 citations
,
April 2019 in “ACS Biomaterials Science & Engineering” This study found that a new SIS-PEG sponge promoted rapid skin defect healing in mice and showed potential for reconstructing reconstituted skin with regenerated hair.
6 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” This study found that the alkaloids cepharanthine and berbamine bind to SK2 and SK3 channel subtypes with affinities that match their concentrations active against various diseases, prompting further investigation into SK channels' role in their therapeutic effects.
November 2025 in “Frontiers in Oncology” This study found that Si extract, cryptomeridiol, and SiAgNPs have the ability to induce cell death and prevent cell growth in HepG2 liver cancer cells, suggesting cryptomeridiol's potential as a phytochemical component in developing new therapies for hepatocellular carcinoma using nanotechnology in vitro.
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that the ethyl acetate extract of Semecarpus anacardium leaves demonstrated cytotoxicity against MCF-7 cancer cells and induced apoptosis, suggesting potential as a cancer treatment with fewer side effects.
April 2018 in “Journal of Ayurvedic and herbal medicine” This study highlights the role of bioinformatics and in-silico studies for identifying drug targets, specifically in herbal drugs, using software and modern techniques to analyze data and model disease pathways before later-stage in vivo and in vitro testing.
51 citations
,
January 2024 in “Nanoscale” This review highlights recent advancements in using nanotechnology to improve the function and delivery of PROTAC drugs, despite existing challenges like low solubility and poor permeability, aiming to enhance their potential in disease treatment.
10 citations
,
May 2018 in “Nutrition and Cancer” This article reviews current research on spice-derived nutraceuticals for treating melanoma and skin cancer, noting emerging evidence that these natural substances may offer preventative and protective benefits against cancer, amidst increased global interest.
1 citations
,
January 2025 in “BIO Integration” This review highlights that the combination of ultrasound and microneedles can enhance transdermal drug delivery by using physical and energy-driven mechanisms to improve drug penetration into deeper skin layers, with implications for precision medicine and chronic disease treatments.
January 2026 in “GSC Biological and Pharmaceutical Sciences” This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against onchocerciasis by targeting proteins in the parasite and its endosymbiont; further research is needed to confirm their efficacy.
25 citations
,
June 2019 in “Endocrine Related Cancer” This review discusses the structure and function of steroid nuclear receptors, particularly focusing on androgen receptor dysregulation in prostate cancer and androgen insensitivity syndromes, without reporting new experimental results.
This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.
This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.
5 citations
,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
March 2026 in “Bioconjugate Chemistry” This review highlights the potential of peptide-based PROTACs (pPROTACs) in expanding the target range of protein degraders beyond small-molecule limitations, particularly for undruggable proteins, by utilizing advances in design, conjugation, and bioPROTAC technology.
February 2026 in “International Journal of Molecular Sciences” In this study, researchers identified 47 proteins associated with male pattern baldness severity and prioritized five candidate genes, including druggable CD38, suggesting new non-hormonal targets for therapeutic development.
December 2025 in “Bioengineering” This review explains that dysregulated sebum secretion and composition contribute to acne and impaired skin barriers while highlighting factors like diet and hormones affecting sebaceous activity, and identifies novel molecular targets and model systems for future therapeutic developments.